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Abstract: Parkinson’s disease is a commonly encountered neurodegenerative disorder primarily 
found in aged populations. A number of medications are available to control symptoms, although 
these are less effective in advanced disease. Deep brain stimulation provides a practicable alter-
native at this stage, although a minority of patients meet the strict criteria for surgery. Novel 
medications that provide enhanced symptomatic control remain in developmental demand. Both 
gene and cell-based therapies have shown promise in early clinical studies. A major unmet need 
is a treatment that slows or stops disease progression.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative disorder, manifested 
  clinically by bradykinesia, resting tremor, rigidity, and postural instability.1 The cause 
of PD is unknown. Although there are a number of medications available for those 
affected, treatment remains focused on these motor, as well as nonmotor, symptoms. 
A number of environmental factors have been implicated in PD.2 However, aging is 
the most significant risk factor for development of the disease. With the number of 
people in the United States aged above 65 years expected to double by 2030,3 a major 
unmet need is new and novel treatments that address both the symptoms of PD and 
its progressive nature.
Since its introduction in 1968,4 levodopa has remained the most efficacious 
treatment of PD. Unfortunately, its use is associated with motor complications such 
as wearing off, dyskinesias, and ‘on–off’ phenomenon.1,5–7 These complications occur 
in about 50% of levodopa-treated patients who have received the drug for more than 
5 years, in 80% of patients treated for 10 years, and in nearly all patients with young-
onset disease.8–10 Additionally, levodopa targets only dopamine deficiency, although 
other neuronal targets, such as acetylcholine, glutamate, and N-methyl-d-aspartic acid, 
may be important.10,11 Novel therapeutic strategies continue to be in developmental 
demand. This review will focus on current medical and surgical treatment strategies 
for PD as well as emerging technologies.
Dopaminergic stimulation
The degeneration of the dopaminergic system associated with PD alters the normal 
physiology of the basal ganglia. There is substantial scientific evidence to support 
that under normal circumstances, dopaminergic neurons in the substantia nigra pars Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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compacta (SNc) fire at a nearly constant rate, independent 
of body movement. This steady firing maintains striatal dop-
amine at a fairly constant level, providing continuous stimu-
lation of striatal dopamine receptors.12–16 However, with the 
progressive loss of dopamine secreting neurons in the SNc in 
PD, striatal dopamine levels become increasingly dependent 
on the availability of peripherally administered levodopa.17 
Immediate-release preparations of levodopa have a half-life 
of 1–3 h,18 the length of which can be modestly increased 
by inhibition of   peripheral   catechol-O-methyltransferase 
(COMT) using either   entacapone or tolcapone.19,20 This 
nonphysiologic stimulation further disrupts an already 
unstable striatum and is believed to be the basis for the motor 
fluctuations seen with chronic levodopa therapy.21,22 In fact, 
continuous   infusion of levodopa has been shown to reduce 
‘off’ time and dyskinesias in patients with PD and motor 
fluctuations,23–25 and   longer-acting dopaminergic drugs, such 
as dopamine agonists, are associated with dyskinesias to a 
lesser extent.26,27 These findings have led to the evaluation of 
long-acting levodopa strategies to treat the motor symptoms 
of PD.28
Continuous dopaminergic 
stimulation with frequent  
levodopa dosing
The Stalevo Reduction in Dyskinesia Evaluation in 
  Parkinson’s Disease (STRIDE-PD) study was a double-blind 
trial comparing the risk of developing dyskinesias in PD 
patients initiated on the combination of levodopa/carbidopa/
entacapone (LCE) versus levodopa/carbidopa (LC) admin-
istered 4 times daily. In the trial, subjects treated with LCE 
demonstrated a shorter time to dyskinesia onset and increased 
frequency of dyskinesias compared to those treated with 
standard LC.29 This occurred despite extended elimination 
half-life and plasma area under the curve of levodopa asso-
ciated with LCE.20 Given the compromise of 4 times daily 
dosing, the authors speculated that the goal of continuous 
dopaminergic stimulation may not have been achieved with 
the chosen dosing frequency.30
An unanticipated outcome of the study was a higher 
  incidence of prostate cancer in those treated with LCE. 
Although it has been postulated that COMT may play a 
protective role, the relationship of COMT inhibition or 
entacapone and prostate cancer is not defined.31,32 The Food 
and Drug Administration (FDA) has announced a safety 
review regarding this imbalance and the possible impact it 
may have on those patients treated with LCE.
Duodenal levodopa
Studies of intravenous and enteral levodopa have shown 
a more predictable motor control and reduced fluctuations 
when compared to oral therapy.33,34 These observations led 
to the development of a concentrated levodopa/carbidopa 
formulation intended for long-term enteral infusion therapy.35 
By providing more consistent plasma levodopa levels, this gel 
formulation (Duodopa®; Solvay Pharmaceuticals,   Bruxelles, 
Belgium) is delivered via a transabdominal port placed 
directly into the duodenum and has proven to be a successful 
therapeutic option.36 Clinical trials have proven the safety and 
efficacy of this delivery method with improvements in both 
motor scores and quality of life measures.37 In one 12-month 
study, the average daily ‘off’ time was reduced from 284 
to 30 min/day, and troublesome dyskinesias were reduced 
from 156 to 40 min/day.25 This therapy is now considered a 
viable treatment alternative for advanced patients.38 Although 
generally reserved as a last-line therapy after subcutaneous 
treatments or deep brain stimulation (DBS) has failed or been 
deemed not feasible, the safety and tolerability of this therapy 
may warrant use earlier in the course of PD.39
Duodopa received approval by the FDA in 2000 as an 
orphan drug and continues to be evaluated for its clinical 
use. There are currently nine studies under way to further 
clarify the efficacy of enteral levodopa. The DuoCOMT 
study is designed to determine the effects of oral COMT 
  inhibitors, in the form of tolcapone and entacapone, on 
plasma concentrations of parenterally delivered levodopa.40 
The medication’s effect on the sympathetic nervous system,41 
its cost–benefit versus standard PD treatments,42 as well as 
its pharmacodynamics continue to be evaluated in controlled 
studies.43 Although there have certainly been difficulties 
associated with the delivery system such as tube dislocations 
and clogging, demand for alternative treatments continues to 
drive improvements in parenteral levodopa delivery.38
Levodopa formulations
After oral ingestion, levodopa is actively transported in the 
duodenum by a specific, large neutral l-amino acid carrier.18 
To reach this site, it must pass through the stomach where it 
is subject to erratic gastric emptying in a high percentage of 
patients with PD.44,45 Because there is no gastric absorption, 
irregular gastric emptying is a major obstacle in the plasma 
concentration of levodopa and may contribute to motor 
fluctuations in advanced disease.46
Liquids pass through the stomach more quickly than 
solids and reach the small intestine faster, perhaps ensuring Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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more rapid and efficient absorption.47 Melevodopa is an 
effervescent prodrug with about 250 times higher water 
solubility compared to tablet levodopa, which allows faster 
and more consistent absorption and a more rapid onset 
of action (Table 1).48,49 This quicker and a more predictable 
time to effect allows improved mobility for patients which 
can translate into less daily ‘off’ time, a useful measure of 
drug efficacy in PD patients.49 Effervescent formulations 
continue to   demonstrate safety and tolerability in clinical 
trials and warrant further exploration.50
Two other levodopa formulations are currently in 
  development in an attempt to improve absorption. XP21279 
is a levodopa prodrug that is designed for absorption 
by transporter mechanisms expressed throughout the 
entire gastrointestinal tract, not just the duodenum, and is 
  currently in Phase I trials.51,52 IPX066 is an extended-release 
  carbidopa–levodopa formulation fashioned to produce quick 
and   sustained concentrations of levodopa with the goal 
of improved and more reliable control of PD symptoms. 
It proved its superiority to immediate-release levodopa 
in a study of 27 PD patients with at least 3 hours of daily 
‘off’ time.53 IPX066 decreased ‘off’ time by 2 hours and 
increased ‘on’ time by nearly 2 hours without a significant 
increase in troublesome dyskinesias. APEX-PD is a Phase III 
randomized, double blind, placebo-controlled study under 
way to evaluate the safety and efficacy of IPX066 over 
30 weeks.54 The sustained action may help to reduce dosing 
frequency and improve compliance as well.
Adenosine A2A antagonists
Several nondopaminergic therapies have been explored in the 
treatment of PD and the adenosine A2A   receptors antagonists 
seem promising. Of the four subtypes of adenosine   receptors, 
the A2A subtype is densely localized in the basal   ganglia. 
Here, they are concentrated on γ-aminobutyric acid (GABA)-
containing medium spiny neurons of the indirect pathway that 
project from the striatum to the   globus pallidus externa.55,56 
Antagonism of adenosine A2A receptors   facilitates intrastriatal 
GABA release, reducing striatopallidal   neuronal overactivity. 
This reduction helps to increase indirect inhibitory output 
from the striatum to the globus pallidus, thus restoring balance 
between the basal ganglia output pathways.57,58
Based on encouraging results in both rat and primate 
PD models,59–63 the adenosine A2A receptor antagonist 
istradefylline has been explored in a number of human 
clinical trials. A small Phase I study showed potentiation 
of the antiparkinsonian effects of concomitant low-dose 
levodopa, a measurable prolongation of ‘on’ time, and 
no exacerbation of dyskinesias.64 A subsequent 12-week, 
randomized, placebo-controlled, double-blind trial in 
levodopa-treated patients with advanced PD demonstrated 
a significant reduction in ‘off’ time, although there was 
a measurable increase in ‘on’ time with dyskinesias.65 
Two large, randomized, double-blind, placebo-controlled, 
Phase II studies also demonstrated significant reductions 
in ‘off’ time over 12 weeks in advanced PD patients, many 
of whom were also   taking multiple adjunctive therapies 
in addition to levodopa.66,67 These results were confirmed 
by a large Phase III clinical trial where istradefylline-
treated patients had a 0.7-hour reduction in daily ‘off’ 
time   compared to placebo, which was sustained over 
12 weeks.68 This reduction in ‘off’ time translated into 
increased functional ‘on’ time in this advanced PD group, 
the vast majority of whom were already taking adjunctive 
therapies. However, these results were not replicated in 
another trial.69 The effect of istradefylline on levodopa-
induced dyskinesias in patients with advanced PD is also 
being investigated.70
A number of other adenosine A2A antagonists are 
currently under development as well, some of which have 
early clinical data. Initial reports concerning vipadenant 
(BIIB014/V2006) were promising, but this compound 
will not be developed, secondary to interest in favor of 
‘next generation’ A2A antagonists held by that   sponsor. 
These are expected to enter early Phase I studies in 
2011.71 Preladenant has reached a Phase II, randomized, 
placebo-controlled trial in moderate to severe PD patients 
with motor fluctuations and dyskinesias. In this setting, it 
showed significant reductions in ‘off’ time and increased 
‘on’ time without exacerbation of dyskinesias.72–74   Further 
studies of preladenant are ongoing in both early and 
advanced PD patients.75,76 ST-1535 is another potential 
candidate   currently in Phase I development by   Sigma-tau 
(Gaithersburg, MD).77 SYN-115, in development by 
  Synosia (Basel, Switzerland), will soon enter Phase IIb 
trials after encouraging functional magnetic resonance 
imaging (fMRI) and early clinical data.78
Perhaps more exciting than symptomatic improvement 
with adenosine A2A antagonists is data suggesting a neu-
roprotective one. Higher intake of caffeine, a nonselective 
adenosine antagonist, has been shown in a number of studies 
to have a protective effect on development of PD in diverse 
populations.79–82 These encouraging findings have translated 
into similar results in both mice and primate models of PD, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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which have demonstrated a reduction in neuronal loss with 
concomitant use of A2A antagonists.83–85 The mechanism of 
this apparent protection is not well understood, although it 
may be a result of altered release of glutamate and aspartate 
in the brain.86
Monoamine oxidase B inhibitors
Inhibitors of monoamine oxidase type B (MAO-b) are 
  receiving renewed attention based on two recent   trials 
investigating a possible disease-modifying effect of 
  rasagiline, an MAO-b inhibitor shown to have neuroprotective 
effects in animal models of PD.87,88 In an attempt to overcome 
the   barriers to the study drug washout, the previous method 
to   separate disease modifying from symptomatic treatment 
effect, a delayed-start design was employed. In this para-
digm, the early start group received the active study drug 
for the full period of the study and the delayed start group 
received a placebo through the first phase of the study. After 
a predetermined period of time, the placebo group switched 
to active therapy, and both groups received the active drug for 
the second phase. Any difference measured between the two 
groups at the end may be interpreted as a disease-modifying 
effect of the medication.
An initial, 12-month study of rasagiline using this unique 
design demonstrated less progression in terms of total 
Unified Parkinson’s Disease Rating Scale (UPDRS) scores 
for those randomized to immediate treatment compared to 
those delayed by 6 months.89 The authors concluded that one 
explanation for these findings is a disease-modifying effect 
of the medication, a slowing of motor disability progression. 
Based on these results, the Attenuation of Disease Progression 
with Rasagiline Once-daily (ADAGIO) study was developed. 
This larger, double-blind, placebo-controlled, delayed-start 
trial was designed to further evaluate whether rasagiline was 
able to affect the rate of progression of PD in patients over 
72 weeks.90 Subjects randomized to early lower dose (1 mg/
day) treatment met all prespecified endpoints showing a 
sustained slower rate of progression and significant improve-
ment in the change in total UPDRS score compared to those 
delayed to treatment. Although those randomized to early 
higher dose (2 mg/day) did show a slower rate of progression 
compared to those delayed to treatment, the change in total 
UPDRS did not differ significantly. These confounding 
results suggested a disease-modifying effect for lower dose 
rasagiline, although the same conclusion could not be drawn 
for higher dose. Rasagiline remains a useful treatment in both 
early and moderate PD, but its neuroprotective properties 
continue to be the subject of much debate.91,92
Safinamide is an aminoamide derivative with   multiple 
mechanisms of action, currently in Phase III clinical trial 
development. It acts as a highly selective, reversible inhibitor 
of MAO-b, reduces the reuptake of dopamine, blocks 
voltage-dependent sodium/calcium channels, and inhibits 
glutamate release.93,94 This combination of actions sug-
gests some potential for neuroprotection and symptomatic 
relief in PD. An early study showed that safinamide was 
associated with improved motor UPDRS scores in early 
PD patients especially when added to those on dopamine 
agonist monotherapy.95 It is now being investigated as an 
adjunct therapy for patients stabilized on levodopa. Early 
results from a 6-month, Phase III, double-blind, placebo-
controlled trial indicate significant improvement in ‘on’ time, 
1.3 hours/day in the treatment group compared to 0.7 hours/
day in the placebo group.96 This improvement came without 
an increase in troublesome dyskinesias. Significant improve-
ments in daily ‘off’ time, ‘off’ time after the first morning 
levodopa dose, UPDRS III during ‘on’ phase, and clinical 
global improvement change and severity scores were also 
reported. Further trials are ongoing to investigate the effect 
of safinamide on levodopa-induced dyskinesias and motor 
fluctuations.97,98
Dopamine agonists
Dopamine agonists provide an important option in the 
treatments available for PD, and there is long-term data to 
support their efficacy and safety. Compared to levodopa, 
  dopamine agonists provide modest symptomatic benefit 
and are associated with higher incidence of side effects 
such as hallucinations, edema, sudden sleep attacks, 
and impulse control disorders (ICD).99 However, motor 
  fluctuations such as dyskinesias are less common with these 
medications.99–101
In the Comparison of the Agonist Pramipexole   versus 
Levodopa on Motor Complications of Parkinson’s   Disease 
(CALM-PD) study, patients were randomized to initial 
treatment with either levodopa or pramipexole and followed 
for up to 4 years. A subset of patients were evaluated with 
regular [123I]β-CIT SPECT imaging to follow the rate of 
  dopamine transporter (DAT) loss as a measure of dopamin-
ergic   neuronal concentration in the striatum. There was a 
  significant reduction in transporter loss at each time point 
over the 46 months in the pramipexole group.102 Similar 
results were seen in the Ropinirole as Early Therapy versus 
l-dopa Positron Emission Tomography (REAL-PET) study, 
which used  18F-dopa positron emission tomography as a 
biomarker of neuronal degeneration in a similar study design. Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Again, there was a significant reduction in tracer uptake 
decline in the ropinirole group compared with the levodopa 
group over 2 years.103 These findings offered evidence of 
a possible disease-modifying effect of dopamine agonists, 
something that had been demonstrated in vitro previously.
The PRamipexole On Underlying Disease (PROUD) 
study utilized a delayed start design to examine whether 
immediate treatment with pramipexole 1.5 mg/day had any 
evidence of disease modification compared to delayed treat-
ment. After 15 months, there was no significant difference 
between the two groups in terms of change in total UPDRS 
score from baseline, suggesting no modification of disease 
over this   period.104 A subset of 150 patients underwent striatal 
DAT density evaluation by [123I] FP-CIT SPECT to compare 
decline in neuronal density, and these results may shed further 
light on any lasting benefit in disease progression.105
Both ropinirole and pramipexole have recently been 
approved as once daily prolonged-release formulations, 
providing important additions to the treatment options in 
both early and advanced PD. In comparator   studies between 
immediate- and prolonged-release formulations, both 
medications showed similar efficacy in treating motor 
symptoms. The Efficacy and Safety Evaluation in PD–Mono-
therapy (EASE-PD Monotherapy) study was a multicenter, 
randomized,   double-blinded, crossover study involving 161 
PD patients that proved noninferiority between ropinirole 
immediate release and ropinirole prolonged release.106 It 
also showed that an overnight switch from immediate to pro-
longed release with an approximate 1:1 conversion was well 
  tolerated. Of great importance, especially when considering 
treatment options, was the finding that overall compliance 
was significantly better in the once-a-day prolonged-release 
group compared to the three-times-a-day immediate-release 
group. The Efficacy and Safety Evaluation in PD–Adjunct 
(EASE-PD Adjunct) study randomized 393 advanced PD 
patients who were suboptimally controlled on levodopa 
to either prolonged release ropinirole or placebo in a 1:1 
fashion.107 The authors found significant improvement in 
daily ‘off’ time, evident as early as 2 weeks after treatment 
initiation,108 UPDRS motor scores, and the ability to sub-
stantially lower daily levodopa dose.
Extended-release pramipexole also showed similar 
efficacy to immediate-release formulation in an 18-week, 
randomized, double-blind, placebo and active comparator-
controlled trial.109 A total of 259 patients were randomized 
to either extended-release pramipexole, immediate-release 
pramipexole, or placebo in a 2:2:1 ratio with rescue levodopa 
allowed if deemed necessary. Both pramipexole groups 
showed significant improvement in PD symptoms to a 
similar degree compared to placebo. Again, the potential for 
increased compliance with once daily dosing is an attractive 
option with the extended-release formulation.
One frequent limiting factor in the use of dopamine 
  agonist is the development of ICD. Increased incidence 
of pathologic gambling, compulsive sexual behavior, 
compulsive buying, and binge or compulsive eating 
have garnered increased attention in PD and can have a 
devastating impact on the lives of those affected.110–113 ICD 
are under-reported in clinical practice, although up to 17% 
of PD patients taking a dopamine agonist may be affected.113 
The DOMINION study, a cross-sectional study of over 3000 
PD patients treated with at least one PD medication for at 
least 1 year with a demonstrable response, showed a 2- to 
3.5-fold increased risk of ICD associated with dopamine 
agonist   treatment.114 However, levodopa-treated patients 
also experienced ICD, especially with higher doses. In this 
population, all ICDs were seen with similar frequency, 
and more than a quarter of patients had more than one 
concurrent ICD. This further highlights the need for proper 
patient education and screening during treatment with 
these medications, as many patients will not volunteer such 
difficulties.113
Amantadine showed marked benefit in a small study of 
17 PD patients with severe pathologic gambling that did not 
improve with medication reduction or behavioral strategies.115 
The authors hypothesized that the antiglutamatergic actions 
of amantadine may underlie its effectiveness. However, in 
the DOMINION patient population, amantadine use was 
associated with a higher incidence of at least one active 
ICD when compared to no amantadine use.116 This remained 
true after controlling for dopamine agonist use as well as 
levodopa dosage and highlights the need for further research 
to elucidate its relationship with ICD. A study evaluating 
whether naltrexone, an opioid antagonist, improves ICD 
symptoms is under way.117
Nanotechnology
One of the most formidable limitations to drug efficacy in PD 
is restricted entry to the central nervous system (CNS) by the 
blood–brain barrier (BBB). The BBB allows the free passage 
of small lipophilic molecules; however, large, hydrophobic, 
or charged molecules require facilitated transport. Dopamine, 
a polar compound, is restricted from free entry into the CNS. 
Nanotechnology can overcome this impediment by packaging 
drugs into small (10–1000 nm) nanoparticles, which more 
readily cross the BBB.118 In addition, these structures can Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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avoid traditional degradation lines and better target specific 
CNS structures, helping to reduce systemic side effects.119 
Ideally, nanoparticles would be part of a system able to 
automate drug delivery, sensing when medication is needed 
and delivering it to a specific target.120
Perhaps more intriguing, nanotechnology has   potential 
applications in treatments that reduce and reverse neuropathol-
ogy as well as promote the regeneration of damaged neurons. 
With the ability to target signaling pathways, gene products, 
and protein aberrations involved in neurodegeneration, nano-
therapies may provide unique neuroprotective strategies.121
DBS
Since it was first discovered that high-frequency stimulation 
of deep brain structures was able to replicate the therapeutic 
effect of lesioning procedures, surgical techniques to treat 
PD have continued to evolve.122–125 DBS is now the   preferred 
surgical procedure to treat advanced PD and is more effective 
at treating motor disability and improving quality of life in PD 
patients with motor fluctuations than best medial therapy.126,127 
Using microelectrode recording, electrophysiological 
  exploration of the target structures is undertaken under local 
or general anesthesia. Local anesthesia allows the advantage 
of intraoperative testing of the effects of DBS and perhaps 
more precise localization.127 Once the optimal target is found, 
the electrode is replaced by a chronic lead, which will then be 
fixed to a pulse generator implanted under the skin, typically 
in the subclavicular area.
The most common target for DBS in PD is the 
subthalamic nucleus (STN). However, the globus pallidus 
interna (GPi) has often been considered a target for patients 
with severe dyskinesias. A recently published randomized 
trial comparing the two targets in 299 patients with 
idiopathic PD showed no significant difference in terms of 
change in motor function from baseline to 24 months.128 
Function was blindly assessed using the UPDRS III, with 
a   reduction of 10.7 points in the subthalmic-stimulation 
group and a reduction of 11.8 points in the GPi group. 
However, a number of nonmotor elements did show a notable 
difference. Those in the subthalamic group showed a signifi-
cant   worsening in depression and visuomotor speed, while 
those in the pallidal group required more dopaminergic 
medication. Both groups rated comparably in quality of 
life measures. The authors concluded that both are feasible 
targets and that nonmotor measures are important determi-
nants in target selection.
As PD advances, falls and gait freezing become a major 
source of disability for patients. These symptoms are not 
well managed with current pharmacotherapy options or DBS 
targets. Stimulation of the pedunculopontine nucleus (PPN) 
has been explored as a target to improve postural instability 
in advanced PD. Early open-label studies demonstrated the 
safety of the procedure and detailed encouraging results 
in terms of motor function.129,130 However, the outcomes 
of recent blinded studies have been mixed. In six patients 
with advanced PD, unilateral PPN stimulation showed no 
objective motor benefit, although improvement in patient 
reported falls after 1 year.131 Similarly, freezing of gait 
showed a modest improvement in another small study while 
other motor symptoms were unchanged.132
The exact mechanisms of action of high-frequency 
stimulation are not known. Electrically jamming the area 
with high-frequency stimulation may interrupt an irregular 
feedback loop or abnormal oscillatory activity in a similar 
manner to lesioning.133,134 Alternatively, direct recording 
during stimulation has shown a change in the neuronal 
Table 1 Medications currently in development for the treatment of Parkinson’s disease
Drug Classification Mechanism Clinical benefit
Melevodopa effervescent levodopa prodrug Converted to dopamine improves motor symptoms
XP21279 Levodopa prodrug Converted to dopamine improves motor symptoms
iPX066 Long-acting levodopa Converted to dopamine improves motor symptoms
istradefylline Adenosine A2A antagonist Reduces striatal-pallidal firing improves motor symptoms 
Potential for neuroprotection
Preladenant Adenosine A2A antagonist Reduces striatal-pallidal firing improves motor symptoms 
Potential for neuroprotection
ST-1535 Adenosine A2A antagonist Reduces striatal-pallidal firing improves motor symptoms 
Potential for neuroprotection
SYN-115 Adenosine A2A antagonist Reduces striatal-pallidal firing improves motor symptoms 
Potential for neuroprotection
Safinamide MAO-b inhibitor 
Reduces reuptake of dopamine 
inhibits glutamate release
Multiple improves motor symptoms 
Potential for neuroprotection
Abbreviation: MAO-b, monoamine oxidase type B.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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frequency and firing pattern in the area being stimulated.135 
Even the downregulation of certain local neurotransmitters 
and/or hormones may play a strong role as shown by the effect 
of high-frequency stimulation on cultured cells.136
There is emerging interest around a possible neuropro-
tective effect of DBS. A number of preclinical studies have 
shown evidence of protection against nigral dopaminergic 
neuronal degeneration in experimental models of PD in 
both rats and primates.137–142 These authors suggest that 
the increased activity in the STN may generate glutamate 
excitotoxicity, which in turn could lead to the degeneration 
of dopaminergic neurons in the SNc causing disease 
progression.143–145 Therefore, altering the activity of the 
STN may remove or inhibit a source of glutamatergic input 
to the SNc leading to protection of dopaminergic cells.138,142 
An alternative explanation may be that an increase in 
brain-derived neurotrophic factor associated with DBS is 
responsible for the neuroprotective effects.142
Patients eligible for DBS are those with clinically 
diagnosed idiopathic PD who are experiencing   disabling 
motor fluctuations despite optimal drug titration, in absence of 
severe dementia (Mini-Mental State   Examination score .24), 
and remain responsive to levodopa therapy.127,146–148   Currently, 
the mean disease duration is 14 years before STN-DBS is 
performed, and less than 5% of PD patients meet eligibil-
ity criteria.149,150 If, in fact, DBS offers neuroprotection to 
dopaminergic cells in the SNc, there will be a substantial 
degree of disease progression and cell loss in the typical DBS 
patient prior to intervention. Interest has, therefore, developed 
regarding early DBS with encouraging results in regards to 
quality-adjusted life expectancy.151 Two   studies are currently 
evaluating the potential for early DBS. The first defines early 
PD as aged younger than 60 years and is evaluating the dif-
ference in Parkinson’s Disease Questionnaire-39 (PDQ-39) 
scores at 24 months in mild to moderate PD patients with 
motor fluctuations and disease duration for greater than 4 
years.152 The second is a prospective, randomized trial com-
paring the time to reach a 20% worsening in UPDRS motor 
score and a reduction in medication 24 months after STN-
DBS in patients 50–75 years old on dopaminergic therapy 
for 6 months to 4 years.153
Gene therapy
The theory that a denervated CNS can be functionally 
repaired by packaging the deficient enzymatic machinery 
and delivering it back where it has been lost is an attractive 
option, especially when exploring treatment options for 
neurodegenerative diseases such as PD. This elegant concept 
was first envisioned for the treatment of single-gene heritable 
diseases such as Lesch–Nyhan syndrome in the mid-
1900s.154,155 Since that time, this concept has expanded to 
include more complex disease states, allowing gene therapy 
to enter the conversation as a viable goal in treatment of PD. 
This technique is currently being tested in a number of Phase I 
and II clinical trials using viral vectors as a means to transport 
enzymes to the striatum of PD patients, in hopes of providing 
both symptomatic benefit and possibly neuroprotection in 
this progressive disease.
In PD, the selective degeneration of dopaminergic 
neurons from the SNc is coupled with the loss of dopamine 
synthesizing enzymes and the brain’s ability to produce 
this essential catecholamine.156 The goal of gene therapy 
is to restore the ability of the brain to once again deliver 
dopamine to the arid striatum. Packaging novel genes into 
viral vectors and delivering them to the brain with the goal of 
enhancing in vivo dopamine production is now under active 
therapeutic evaluation. Adeno-associated virus (AAV) has 
been the most commonly utilized vector for such purposes 
thus far due to its ease of use and safety profile.157,158 The 
potential benefits are compelling: the ability for selective 
basal ganglia stimulation by bypassing the need for sys-
temic medications, the avoidance of undesirable side effects 
induced by indiscriminate dopamine activation, and even the 
possibility for individualized treatment regimens.
Shen et al have used AAV vectors expressing tyrosine 
hydroxylase (TH), l-amino acid decarboxylase (AADC), 
and GTP cyclohydrolase 1 (GCH1) and shown sustained 
behavioral improvement in 6-hydroxydopamine (6-OHDA)-
lesioned rats.158 Muramatsu et al stereotactically injected 
four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
treated monkeys in the unilateral putamen with these vectors. 
Using the primate parkinsonian rating scale (PPRS), the 
animals showed marked behavioral improvement that was 
sustained for up to 10 months. In addition, they were able to 
demonstrate greater than 90% transduction of the injected 
putamen based on immunostaining.159
More recently, efforts have been made to deliver all three 
functional genes in a single viral vector with the goal of 
more efficient delivery and translational efficacy.   ProSavin 
(owned by Oxford Biomedica, Oxford, UK) developed 
a lentiviral-based vector. A study in MPTP-treated pri-
mates showed significant motor benefit starting 2 weeks 
after transfection with sustained benefit up to 44 months. 
Positive effects toward dyskinesias as well as off-time 
d  ystonia were also   demonstrated.160 With these   encouraging 
results, six   Parkinson’s patients have been injected in a Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Phase I/II study. Two of three in the initial low-dose group 
have shown a 30% improvement in the UPDRS III ‘off’ 
score at 2 years.161 This initial dose-escalation trial will be 
followed by a second phase to confirm the efficacy of the 
optimal dose in a randomized trial.162
An alternative approach under investigation is the 
delivery of AADC to the striatum as a means to increase the 
conversion efficiency of exogenously administered levodopa 
into active dopamine. This concept was first explored in 
MPTP-lesioned primates who showed higher conversion 
rates of l-dopa to dopamine following AADC gene 
transfer.163 Two recent Phase I trials have been completed 
using this technique, both showed a significant improvement 
in ‘off’ time measured by UPDRS at 6 months, with trends 
in improvement in ‘on’ time. The majority of patients were 
able to reduce their total dose of levodopa. Positron emission 
tomography (PET) with 6-[18F]fluoro-l-m-tyrosine (FMT), 
a tracer for AADC, showed sustained AADC activity in the 
putamen for as long as 96 weeks.164,165
The concept of continuous dopamine delivery has been 
explored in the setting of levodopa-induced dyskinesias.17,166–168 
Using gene therapy to attain such a state has been explored 
in rat models of PD with some success. One such study 
used recombinant adeno-associated viral (rAAV) to deliver 
the TH and GCH1 genes to the striatum of lesioned rats 
rendered dyskinetic with daily, pulsatile levodopa injections. 
The magnitude of dyskinesias was reduced by 85%, and in 
four of the nine animals, the dyskinesias were completely 
eliminated.169
Taking a different approach to gene transfer, Kaplitt et al 
used an AAV viral vector to deliver varying concentrations 
of the glutamic acid decarboxylase (GAD) gene directly 
into the STN of 12 patients. GAD catalyzes the synthesis 
of GABA, the major inhibitory neurotransmitter in the 
brain. The   procedure was well tolerated and demonstrated 
  significant improvement in motor UPDRS scores for as 
long as 12 months along with corresponding changes on 
FDG-PET. However, given that this was an open-label inves-
tigation, further double-blind trials will be needed to explore 
the benefit of this method.170,171
Unfortunately, no available treatment has yet proven to 
have a definitive neuroprotective effect for patients with 
PD.172 However, the concept of delivering trophic factors to 
the CNS has evolved considerably to become a major topic 
in this conversation. Most of the attention has revolved 
around glial-derived neurotrophic factor (GDNF) since it 
was first discovered to have a potent protective effect on 
the survival of midbrain dopaminergic neurons.173 Although 
initial studies with GDNF were disappointing, this was 
attributed to limited CNS penetration as the trophic factors 
were delivered via intraventricular cannula.174,175 A number 
of studies have now shown the feasibility of using rAAV 
to deliver GDNF to the rat striatum and its neuroprotective 
effect against dopaminergic cell loss following lesioning with 
6-OHDA.176,177 In addition, GDNF delivery using a lentiviral 
vector showed prevention of nigrostriatal degeneration and 
induction of cell regeneration in MPTP-treated primates.178 
However, GDNF was unable to prevent cell loss in a genetic 
model of PD using an intranigral injection of mutant human 
alpha-synuclein via lentiviral vector in rats.179
Delivery of GDNF has been studied by way of continuous 
intraparenchymal infusion into the posterior putamen in 
human PD patients as well. In one Phase I trial, the procedure 
was well tolerated and resulted in significant improvement 
in motor performance in both the ‘off-’ and ‘on-’ medication 
states at 24 months.180,181 However, a randomized, double-
blind, placebo-controlled, parallel-group study failed to show 
a significant improvement in the UPDRS motor ‘off’ score 
with bilateral GDNF infusion.182
Other trophic factors in the tumor necrosis factor α family 
are possible targets for neuroprotection in PD as well includ-
ing neurturin (NTN), the naturally occurring analog of GDNF. 
NTN has also shown protection of dopaminergic nigral neu-
rons following 6-OHDA lesioning in rats up to 6 months.183,184 
Additionally, MPTP-treated monkeys demonstrated protec-
tion of nigral neurons, preservation of dopaminergic striatal 
innervation, and prevention of motor dysfunction following 
injection with an AAV-based vector encoding human NTN.185 
With these encouraging results, Ceregene Inc (San Diego, 
CA) completed a Phase I study in which 12 Parkinson’s 
patients received   AAV2-NTN (Cere-120) injected into the 
bilateral putamen in either a low- or high-dose range. The 
procedure was proven safe, and there was a statistically sig-
nificant improvement in the UPDRS score in the practically 
defined ‘off’ condition, a secondary measure of the study.186 
A Phase II study is currently under way comparing the change 
in ‘off’ time between Cere-120 and placebo in patients with 
advanced PD.187
Nonviral vectors for the safe and effective transfer of 
genes is a focus of nanotechnology as well, although they 
may lack the high transfection rate obtained with viral 
vectors.121 Amino-functionalized organically modified silica 
nanoparticles have been shown to bind and protect plasmid 
DNA from enzymatic digestion and to provide effective cell 
transfection in vitro.188 These gene-containing nanoparticles 
may become an effective alternative to restore deficient Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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enzymes and deliver neurotrophic factors directly where 
needed (Table 2).
Conclusion
PD is a commonly encountered neurodegenerative disorder 
of impaired voluntary movements as well as many 
nonmotor symptoms. Although it has been well recognized 
within the medical community since its first description 
by James Parkinson,189 the cause of PD remains unknown 
and the treatment symptomatic. However, since levodopa 
revolutionized care in the 1960s, there has continued a 
torrent of medical and surgical advances that now provide 
the clinician a number of viable treatment options. The quest 
for novel treatments, disease-modifying therapeutics, as well 
as a definitive cure, remains fervent with both basic science 
and clinical research continuing to add to our understanding 
of this disabling disorder.
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